Mild intermittent allergic rhinitis was found in 2.0% of patients, moderate to severe intermittent allergic rhinitis in 18.2% of patients, mild persistent allergic rhinitis in 5.6% of patients and moderate to severe persistent allergic rhinitis in 74.3% of patients.
Most patients had mild intermittent (36.1%) or mild persistent (46.8%) allergic rhinitis (Table 1).
LABAs are recommended only as add-on therapy to ICSs for moderate or severe asthma, but not for mild persistent asthma or allergic rhinitis, or as asthma monotherapy.
Patients with mild persistent asthma and allergic rhinitis, who were taking an ICS either alone or in combination with a LABA, started concomitant MON treatment as part of their routine care.
In this observational study of combination drug treatment of mild persistent asthma and allergic rhinitis, no difference was observed between LABA/ICS/MON combination therapy and the ICS/MON combination without LABA use, for the rate of asthma attacks over one year.
We analyzed the subgroup of patients having a physician's diagnosed with mild persistent asthma and concomitant allergic rhinitis.
This was a post-hoc analysis of a cohort study of adults 15 55 years of age, with mild persistent asthma and concomitant allergic rhinitis, in three European countries (Italy, Spain, and Poland) from January 1 , 1998to December 31 , 2003
Asthma is classified based on the degree of symptom severity, which can be divided into four categories: mild intermittent, mild persistent, moderate persistent, and severe persistent.
Four clusters were identified (severe persistent, moderate persistent, mild persistent, and fluctuating).
In conclusion, we found a high proportion of moderate to severe persistent rhinitis in patients consulting general practitioners.
